ORIGINAL RESEARCH article

Front. Oncol.

Sec. Molecular and Cellular Oncology

Volume 15 - 2025 | doi: 10.3389/fonc.2025.1577859

MiR-221, miR-320a, miR133a, and miR-133b as potential biomarkers in leiomyosarcoma

Provisionally accepted
Nasrin  Mst AkhtarNasrin Mst AkhtarAnnabell  WalterAnnabell WalterKathrin  KatenkampKathrin KatenkampYuan  ChenYuan ChenThomas  LehmannThomas LehmannWolfram  WeschenfelderWolfram WeschenfelderChristian  SpiegelChristian SpiegelMatthias  VogtMatthias VogtGunther  O HofmannGunther O HofmannAndreas  HochhausAndreas HochhausNikolaus  GaßlerNikolaus GaßlerJoachim  H ClementJoachim H ClementKarin  G SchrenkKarin G Schrenk*
  • University Hospital Jena, Jena, Germany

The final, formatted version of the article will be published soon.

Background: Leiomyosarcoma is an aggressive tumor with a high rate of distant metastasis and poor prognosis. No standardized biomarkers are available to assess early diagnosis or monitoring during the clinical course. MicroRNAs (miRNAs) function in modulating a multitude of targets and are involved in tumorigenesis, cancer progression, and metastasis. This study was designed to evaluate miR-221, miR-320a, miR-133a, and miR-133b as potential biomarkers in leiomyosarcoma.The expression levels of miR-221, miR-320a, miR-133a, and miR-133b as well as their target mRNAs CDKN1B, TGFBR1, and IGF1R were assessed by quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) in tissue samples from 33 patients with leiomyosarcoma. Wilcoxon test, Kruskal-Wallis test, Mann-Whitney test as well as Spearman-Rho-test were used for statistical analysis. Receiver operating characteristic (ROC) analyses were performed to discriminate metastatic risk of local and primary tumors in correlation to miR-221, miR-320a, miR-133a, and miR-133b.The expression levels of miR-221, miR-320a, and miR-133a were significantly upregulated in leiomyosarcoma tumor tissue compared to adjacent non-tumor tissue (p = 0.003 for miR-221, p = 0.006 for miR-320a, and p = 0.044 for miR-133a respectively). The target mRNAs CDKN1B, TGFBR1, and IGF1R in 25 leiomyosarcoma tumor tissues were not significantly deregulated. There was no significant upregulation in primary tumors and metastases compared to local tumors for miR-221, miR-320a, miR-133a, and miR-133b. ROC curves of miRNA-221, miR-320a, miR-133a, and miR-133b to predict metastatic risk at initial presentation of the tumor, comparing non-metastasizing and metastasizing leiomyosarcomas, demonstrated no significant levels.Conclusion: miR-221, miR-320a, and miR-133a were significantly upregulated in leiomyosarcoma tumor tissue as compared to adjacent non-tumor tissue. There was no significant difference in miRNA expression and ROC curves in primary tumors as compared to local tumors. While not statistically significant, ROC curve of miR-133b suggests a potential role in predicting metastatic risk, warranting subsequent analysis. This study provides evidence for further evaluation of miR-221, miR-320a, miR-133a, and miR-133b as biomarkers in primary diagnosis and assessment of metastatic risk in leiomyosarcoma.

Keywords: miRNA, miR-221, MiR-320a, miR-133a, miR-133b, Sarcoma, biomarkers

Received: 16 Feb 2025; Accepted: 29 May 2025.

Copyright: © 2025 Akhtar, Walter, Katenkamp, Chen, Lehmann, Weschenfelder, Spiegel, Vogt, Hofmann, Hochhaus, Gaßler, Clement and Schrenk. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Karin G Schrenk, University Hospital Jena, Jena, Germany

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.